Shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) have earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $443.14.
A number of equities research analysts recently commented on MEDP shares. Guggenheim increased their price objective on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. TD Cowen began coverage on shares of Medpace in a research report on Wednesday, May 29th. They set a “buy” rating and a $452.00 target price on the stock. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and upped their price objective for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. Mizuho began coverage on Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price on the stock. Finally, StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a research report on Friday, June 7th.
Get Our Latest Analysis on MEDP
Insider Buying and Selling
Hedge Funds Weigh In On Medpace
A number of large investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in shares of Medpace by 58.4% during the 2nd quarter. GAMMA Investing LLC now owns 236 shares of the company’s stock worth $97,000 after acquiring an additional 87 shares in the last quarter. American Trust purchased a new stake in shares of Medpace in the 1st quarter valued at approximately $234,000. DekaBank Deutsche Girozentrale boosted its position in shares of Medpace by 3.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 36,030 shares of the company’s stock worth $14,459,000 after purchasing an additional 1,173 shares during the period. Cetera Advisors LLC boosted its position in shares of Medpace by 162.4% during the 1st quarter. Cetera Advisors LLC now owns 2,608 shares of the company’s stock worth $1,054,000 after purchasing an additional 1,614 shares during the period. Finally, Cetera Investment Advisers boosted its position in Medpace by 235.0% in the 1st quarter. Cetera Investment Advisers now owns 11,494 shares of the company’s stock valued at $4,645,000 after buying an additional 8,063 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.
Medpace Stock Down 0.7 %
NASDAQ:MEDP opened at $404.42 on Wednesday. The firm has a 50 day moving average of $397.69 and a 200 day moving average of $369.55. The stock has a market capitalization of $12.53 billion, a price-to-earnings ratio of 41.23, a PEG ratio of 2.04 and a beta of 1.36. Medpace has a 52 week low of $227.21 and a 52 week high of $437.39.
Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. The firm had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same period last year, the firm posted $2.27 earnings per share. As a group, analysts expect that Medpace will post 11.29 EPS for the current year.
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Read More
- Five stocks we like better than Medpace
- What is the Shanghai Stock Exchange Composite Index?
- RXO Shares Surge Following New Acquisition Deal
- Industrial Products Stocks Investing
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.